Red Light Holland Spotlights JAMA Trial Demonstrating Single Psilocybin Dose Cuts Cocaine Use Over Six Months
Filament Health, a Red Light Holland subsidiary, holds exclusive license to pivotal trial data underpinning its Phase 2 botanical psilocybin candidate PEX010 for stimulant use dis…
A peer-reviewed randomized clinical trial published in JAMA Network Open reveals that a single synthetic dose of psilocybin significantly reduced cocaine consumption in adults with cocaine use disorder over a six-month period without serious adverse events. Filament Health Corp., wholly owned by Red Light Holland, hol…
